Blood biomarkers of outcomes after ischemic stroke by Varvne, Josefine
 	   	  	  	  	  	  	  	  	  	  	  	  	  	  THE SAHLGRENSKA ACADEMY 
	  
 
 
 
 
 
 
Blood biomarkers of outcomes after ischemic stroke 
 
 
Degree Project in Medicine 
 
Josefine Varvne 
 
Programme in Medicine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gothenburg, Sweden 2018 
 
 
Supervisor: Christina Jern 
Co-supervisor: Annie Pedersén 
 
Department of Clinical Pathology and Genetics 
Institute of Biomedicine 
Sahlgrenska Academy of Gothenburg 
 
 2 
TABLE OF CONTENTS 
ABSTRACT ............................................................................................................................................. 3 
INTRODUCTION ................................................................................................................................... 5 
DEFINITION OF STROKE, PATHOPHYSIOLOGY AND ETIOLOGY ............................................................. 5 
RISK FACTORS FOR ISCHEMIC STROKE ................................................................................................ 7 
TRENDS IN ISCHEMIC STROKE INCIDENCE ........................................................................................... 7 
POST-STROKE OUTCOMES .................................................................................................................... 8 
Mortality .......................................................................................................................................... 8 
Recurrent stroke .............................................................................................................................. 9 
Neurological and cognitive impairments after stroke ................................................................... 10 
PREDICTIVE FACTORS OF POST-STROKE OUTCOMES ......................................................................... 12 
POTENTIAL PREDICTIVE BIOMARKERS OF POST-STROKE OUTCOMES ................................................ 13 
Inflammatory biomarkers .............................................................................................................. 13 
Genetics ......................................................................................................................................... 14 
NOVEL BIOMARKERS IN THE PRESENT STUDY ................................................................................... 15 
NFL ............................................................................................................................................... 15 
GFRa1 .......................................................................................................................................... 16 
MANF ............................................................................................................................................ 17 
THE IMPORTANCE OF PREDICTIVE BIOMARKERS OF POST-STROKE OUTCOMES ................................ 18 
AIM ........................................................................................................................................................ 18 
MATERIAL AND METHODS ............................................................................................................. 19 
STUDY POPULATION .......................................................................................................................... 19 
ASSESSMENTS OF POST-STROKE OUTCOMES ..................................................................................... 20 
Cause of death and recurrent events ............................................................................................. 20 
Functional and neurological outcomes ......................................................................................... 20 
SUBSTUDY I ....................................................................................................................................... 21 
SUBSTUDY II ...................................................................................................................................... 21 
STATISTICAL METHODS ..................................................................................................................... 22 
ETHICS.................................................................................................................................................. 24 
RESULTS .............................................................................................................................................. 24 
SUBSTUDY I ....................................................................................................................................... 24 
SUBSTUDY II ...................................................................................................................................... 28 
DISCUSSION ........................................................................................................................................ 34 
CONCLUSIONS ................................................................................................................................... 37 
POPULÄRVETENSKAPLIG SAMMANFATTNING ........................................................................ 38 
ACKNOWLEDGEMENTS ................................................................................................................... 39 
REFERENCES ...................................................................................................................................... 40 
APPENDIX ............................................................................................................................................ 45 
	  
 
 3 
ABSTRACT 
Introduction: Today, knowledge about predictors of stroke outcomes is limited and few 
studies have investigated blood biomarkers as predictors of outcomes after ischemic stroke, 
especially in the long-term. 
 
Aim: To investigate if there is an association between circulating concentrations of three 
novel biomarkers and long-term outcomes after ischemic stroke. 
 
Methods: The study population was derived from the Sahlgrenska Academy Study on 
Ischemic Stroke (SAHLSIS), which includes patients with ischemic stroke aged 18-69 years. 
Blood was drawn 3 months after the index stroke. Concentrations of neurofilament light chain 
(NFL) were analysed using a single-molecule array (Simoa) method. Concentrations of glial 
cell-derived neurotrophic factor family receptor a1 (GFRa1) and mesencephalic astrocyte-
derived neurotrophic factor (MANF) were analysed using a proximity extension assay (PEA) 
technique. Associations to post-stroke outcomes assessed as the National Institutes of Health 
Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) at a 7-year follow-up were 
examined using linear and logistic regression, respectively. 
 
Results: Concentrations of all three biomarkers were significantly higher in cases with poor 
(mRS 3-6) compared to good (mRS 0-2) outcome. All biomarkers were associated to NIHSS 
and mRS in the univariate analysis and the multivariate analysis adjusted for age and history 
of stroke. When additionally adjusting for stroke severity, i.e. baseline NIHSS, the association 
to mRS remained for all three biomarkers and the association to NIHSS remained for NFL 
and MANF. For GFRa1 and MANF, physical activity was also included in the model 
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together with the covariates indicated above. In this model, the association for MANF and 
NIHSS remained. 
 
Conclusions: We identified three novel circulating biomarkers that were independently 
associated to neurological and functional outcomes after ischemic stroke. Further research is 
needed to design an assay with a set of biomarkers that effectively predicts post-stroke 
outcomes. 
 
Key words: ischemic stroke, functional outcomes, prognosis, biomarkers  
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INTRODUCTION 
Each year, approximately 10 million people suffer from stroke worldwide (1), of which 25 
000 affects people in Sweden (2). Globally, stroke causes 6.5 million deaths every year (1), 
which makes it the second most common cause of mortality (3). There are currently about 
25.7 million stroke survivors (1), of whom many are suffering from neurological and 
cognitive impairments (4). Thereby, stroke is the third most common cause of disability-
adjusted life-years (DALYs) (5) and causes major socioeconomics consequences on both 
individual and society levels. The cost due to stroke in Sweden is approximately 18 billion 
Swedish crowns every year (6). In addition, the annual cost of spouses’ informal support has 
been estimated to approximately 990 € for independent stroke survivors and 25 000 € for 
dependent stroke survivors (7). 
 
Definition of stroke, pathophysiology and etiology 
Stroke is a disruption of the blood supply to a brain area causing oxygen and nutrient 
deficiency, and accordingly neuronal death. Depending on which area that is affected, 
different neurological symptoms occur. A stroke is either caused by a bleeding, hemorrhagic 
stroke, or by a blood clot (i.e. thrombus or embolus), ischemic stroke (8). This study will 
focus on ischemic stroke. 
 
In high-income countries, roughly 85% of all strokes is due to ischemic stroke (9). However, 
the thrombus or embolus can appear through different pathophysiological mechanisms and 
ischemic stroke is therefore divided into subtypes. One of the most frequently used protocols 
for this is the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification with 5 
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subtypes: 1) large vessel disease (LVD), 2) cardioembolism (CE), 3) small vessel disease 
(SVD), 4) stroke of other determined etiology and 5) cryptogenic stroke (10). 
 
LVD accounts for approximately 15% of all ischemic stroke, but this proportion varies by 
ethnicity (11-13). This subtype of ischemic stroke occurs due to atherosclerosis (14) and is 
characterized by a significant stenosis (>50%) or a complete occlusion in a precerebral (e.g. 
the carotid artery) or cerebral artery. LVD typically causes infarcts >1.5 cm in cerebral cortex, 
brain stem or cerebellum. Accordingly, this subtype causes cerebral cortical dysfunction such 
as aphasia, neglect and paralysis or brainstem or cerebellar impairment. (10) 
 
CE accounts for 25-30% of all ischemic stroke (11-13). The major cause of CE is atrial 
fibrillation, but it may also occur due to recent myocardial infarction, mechanical heart valve 
prosthesis, sick sinus syndrome, dilated cardiomyopathy and infective endocarditis. 
Symptoms and brain imaging results are often similar to those of LVD. (10) 
 
SVD accounts for approximately 20% of all ischemic stroke (11-13) and is caused by an 
occlusion of a deeply located, perforating artery which derives from the circle of Willis or the 
basilar artery (15). Most commonly, SVD causes small infarcts <1.5 cm in basal ganglia, the 
internal capsule, thalamus or brain stem (16) and gives rise to pure motor, sensory or 
sensorimotor strokes (13). 
 
Stroke of other determined etiology account for nearly 5% of all ischemic stroke (11-13), 
although it occurs more frequently among younger stroke patients along with cryptogenic 
stroke (17). The most common cause of stroke of other determined etiology is arterial 
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dissection. Other etiologies are hematologic diseases, vasculitis and coagulopathies (13). The 
clinical findings as well as location and size of the ischemic lesion vary (16). 
 
A stroke is classified as cryptogenic if the etiology cannot be determined despite of an 
extensive diagnostic evaluation (16). About 25-30% of all ischemic stroke is classified as 
cryptogenic (18). Suggested causes of cryptogenic stroke are occult paroxysmal atrial 
fibrillation, paradoxical embolism trough persistent foramen ovale (PFO) and atherosclerosis 
with stenosis <50% (19). When two or more potential etiologies have been found or when the 
clinical work-up is incomplete, the stroke is classified as of undetermined etiology (10).  
 
Risk factors for ischemic stroke 
Several risk factors for ischemic stroke also apply for myocardial infarction because of their 
partly shared etiology (20, 21). The INTERSTROKE study, a case-control study including 
3000 cases with acute first-ever stroke and 3000 age- and sex-matched controls, reports 10 
risk factors that accounted for 90% of the population attributable risk (PAR) for all stroke: 
history of hypertension, current smoking, waist-to-hip ratio (i.e. abdominal obesity), 
unhealthy diet, physical inactivity, diabetes mellitus, high alcohol intake (>30 drinks per 
month or binge drinking), psychosocial stress/depression, cardiac causes (atrial fibrillation or 
flutter, previous myocardial infarction, rheumatic valvular disease, prosthetic heart valve) and 
high ratio of apolipoproteins B to A1. (21) 
 
Trends in ischemic stroke incidence 
Altogether, the incidence of all stroke (1) and ischemic stroke is decreasing (22). However, 
when looking at different ages the change in incidence differs. The average age for first-ever 
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ischemic stroke has decreased, mainly since the incidence of ischemic stroke among younger 
people has increased (23). 
 
In Sweden between 1987 and 2010, the incidence decreased among people aged 45-64 years 
(0.4% for men and 0.6% for women per year) and 64-84 years (3.7% for men, 2.5% between 
1987 and 2005 and 5.1% after 2005 for women per year) but increased among people 18-44 
years of age (1.3% for men and 1.6% for women per year) (22). This might partly be the 
result of an increased prevalence of stroke risk factors such as hypertension, diabetes, obesity, 
hyperlipidemia and smoking among stroke patients aged 15-44 years (24). It has also been 
found that an increase in BMI through puberty and adolescence is associated with stroke in 
adult age (25). 
 
Post-stroke outcomes 
Mortality 
The proportion of patients that die after stroke varies depending on, for instance, subtype of 
stroke and if treated in high- or low-/middle-income countries. According to a review, 13-
35% of the patients have died 1 month after the stroke and at 1 year, 5 years and 10 years 
after stroke, 25-38%, 50-60% and 75%, respectively, have died (26). The FUTURE study, a 
prospective cohort study including stroke patients aged 18-50 years, reports a one-year 
mortality of 2.4%, 5-year mortality of 5.8%, 10-year mortality of 12.4% and 20-year mortality 
of 26.8% (27). Redfors et al. reported a 1-year mortality of 2.0%, 5-year mortality of 9.5% 
and 10-year mortality of 20.2% in patients <70 years of age at the index stroke (28). 
 
The mortality rate is decreasing for both stroke in general (29) and ischemic stroke (30) in all 
ages. In a study of stroke patients aged 18-54 years, the standardized mortality ratio, i.e. the 
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ratio of the observed number of deaths in the study to the expected deaths in the general 
population, was 5.51 (95% CI 5.15-5.88) for men and 7.06 (95% CI 6.37-7.78) for women. 
Fortunately, the mortality risk decreased by 32% in men and 45% in women during the study 
period between 1987 and 2006. (30) 
 
There are several causes of death among stroke patients which, to some extent, varies 
depending on studying short- or long-term mortality. Neurological complications such as 
brain edema, increased intracranial pressure, hemorrhagic transformation and recurrent stroke 
are common causes of death, especially in the acute and subacute phase of stroke (4, 31). 
Other causes of death early after stroke onset are medical complications: infections, mostly 
pneumonia and urinary tract infections, cardiac disease such as ischemic heart disease and 
cardiac arrhythmias (4) and vascular events other than recurrent stroke, i.e. pulmonary 
embolism. Vascular events remain common causes of death together with cardiac diseases 
among stroke survivors for years after the index event (31). The proportion of deaths due to 
the index or recurrent stroke decreases and the proportion of deaths due to cardiac disease 
increases as time passes after stroke onset (32). After a median follow-up time of almost 9 
years, Redfors et al. found that 64.3% of stroke patients died from vascular causes (e.g. 
cardiac causes, ischemic stroke, hemorrhagic stroke) in comparison to 26.5% among controls 
(28). 
 
Recurrent stroke 
According to a review, the cumulative risk of recurrent stroke among stroke survivors, i.e. the 
proportion that experience another stroke after the first one, is 1-4% at 1 month, 7-13% at 1 
year and nearly 40% at 10 years after the index stroke (26). The FUTURE study reports a 20-
year cumulative risk of 19.4% (33). P. Redfors reports recurrent stroke in 9% of stroke 
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survivors 2 years after the index stroke in patients <70 years of age (34). A study of stroke 
patients aged 18-54 years, reported a cumulative four-year risk of recurrent stroke of 11.8% in 
men and 9.8% in women, which is a decrease of 55% in men and 59% in women from the 
first (1987-1991) to the last (2002-2006) four-year period studied (35). 
 
Neurological and cognitive impairments after stroke 
Approximately 50% of stroke survivors are suffering from neurological and/or cognitive 
disabilities and 20% of disabled survivors are institutionalized (4). Common neurological 
impairments after stroke are weakness or paralysis of extremities, spasticity, language 
difficulties, neglect and pain which often affect the ability to perform activities of daily living 
(ADLs) (36). 
 
The modified Rankin Scale (mRS) (Table 1) describes the grade of disability and is used for 
evaluation of functional outcome after stroke. The scale is widely used in clinical trials. The 
original Rankin Scale scored 1-5, whereas the modified scale added a grade, 0, for no 
symptoms. In clinical trials, another grade, 6, for death is usually also used. (37) 
 
Table 1. Description of mRS. 
mRS, modified Rankin Scale. 
Grade Description 
0 No symptoms at all 
1 No significant disability: despite symptoms, able to carry out all usual duties 
and activities 
2 Slight disability: unable to perform all previous activities but able to look after 
own affairs without assistance 
3 Moderate disability: requiring some help but able to walk without assistance 
4 Moderately severe disability: unable to walk without assistance and unable to 
attend to own bodily needs without assistance 
5 Severe disability: bedridden, incontinent and requiring constant nursing care 
and attention 
6 Death 
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The National Institutes of Health Stroke Scale (NIHSS) (Table 2) is a tool for evaluation of 
stroke severity and how the neurological symptoms change over time. It is most commonly 
used during the acute phase of stroke and hospitalization. It involves 11 categories testing 
major neurological functions. For each category, the examiner chooses the description that 
best represents the patient’s result of the test and points are given accordingly. The minimum 
points of 0 is normal and maximum points of 42 represent the worst neurologic symptoms. 
(38) 
 
Table 2. Description of NIHSS. 
Neurological function Description 
1.   Level of 
consciousness 
a.   Level of consciousness: alert – drowsy – stuporous – 
coma 
b.   Questions: ask about the current month and the patient’s 
age 
c.   Commands: “close eyes” and “make fist” 
2.   Gaze Normal – partial gaze palsy – deviation conjugée 
3.   Visual field No visual loss – partial hemianopia – complete hemianopia – 
bilateral hemianopia 
4.   Facial palsy Normal – minor – partial – complete 
5.   Motor arm The patient’s arm is lifted about 90 degrees and the patient is 
asked to keep the arm elevated 
6.   Motor leg The patient’s leg is lifted about 30 degrees and the patient is 
asked to keep the leg elevated 
7.   Limb ataxia Finger-nose and heel down shin 
8.   Sensory Normal – partial loss – severe loss 
9.   Language The patient is asked to name items, describe a picture and read 
sentences 
10.  Dysarthria Evaluated when the patient is asked to read listed words out loud 
11.  Extinction and 
attention 
Identify neglect through previous testing and/or by double 
simultaneous stimuli testing with patient’s eyes closed 
NIHSS, National Institutes of Health Stroke Scale. 
 
In addition to neurological deficits, “hidden” impairments such as depression, cognitive 
dysfunction (4, 36) and fatigue (4) are common post-stroke complications that also affect the 
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mRS score after stroke. Cognitive functions such as executive functions, attention and 
memory are often impaired among stroke survivors, even in patients with good motor 
recovery (39) and when tested several years after the stroke (40). The prevalence of fatigue 
varies, though it is clear that it is a common post-stroke complication that, along with the 
other cognitive impairments mentioned, affects quality of life and the ability to go back to 
work among other things (41). 
 
Predictive factors of post-stroke outcomes 
Older age, severe stroke, history of cardiac disease (e.g. ischemic heart disease, atrial 
fibrillation and congestive heart failure) and vascular disease (e.g. TIA and intermittent 
claudication) are all predictors of mortality among stroke patients (32, 42). Recurrent stroke 
(4), pneumonia and venous thromboembolism (31) also increase the risk of mortality. Stroke 
patients with diabetes mellitus has a higher short- and long-term mortality (43). Considering 
the etiologic subtypes of ischemic stroke, the mortality is highest in patients with CE stroke 
(13, 44). 
 
The short-term risk of recurrent stroke is highest for LVD stroke (13, 44, 45). Diabetes 
mellitus (32, 43) and older age are also predictors of recurrent stroke (32). Similarly to the 
risk factors of mortality, predicting factors of post-stroke disability, most commonly 
measured using mRS, are older age, severe stroke (32), recurrent stroke (4, 32), cardiac 
complications, pneumonia, venous thromboembolism (31), diabetes mellitus (43) and CE 
stroke (13, 44). 
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Potential predictive biomarkers of post-stroke outcomes 
According to the Biomarkers Definition Working Group, a biomarker is “a characteristic that 
is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention”. A biomarker 
can be used to diagnose a patient with a disease, to decide on classification of a disease, to 
predict prognosis as well as predict and evaluate response to treatment (46). Regarding post-
stroke outcomes, there are a few biomarkers that have been suggested to have predicting 
value. 
 
Inflammatory biomarkers 
In patients with ischemic stroke, inflammatory responses are activated due to necrosis 
following hypoxia. Dying neurons release damage signals and activate damage-associated 
molecular patterns (DAMPs), which activate immune cells and enhances the secretion of pro-
inflammatory cytokines. The powerful activation of the immune system during ischemic 
stroke results in a large-scale recruitment of mature and immature immune cells which 
accumulate in the ischemic lesion resulting in further secretion of cytokines and even greater 
brain damage as well as post-stroke immunosuppression with increased risk of complicating 
infections. The inflammatory processes also increase the permeability of the blood-brain-
barrier (BBB) with increased risk of brain edema and hemorrhagic transformation. (47) 
 
Considering the above, some pro-inflammatory proteins have been hypothesized to predict 
poor post-stroke outcomes and some anti-inflammatory proteins have been suggested to 
predict good post-stroke outcomes (Table 3). However, studies have reported somewhat 
contradictive results and it has yet not been clarified whether they add any predictive value in 
the clinical situation. (47-51) 
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Table 3. Summary of studies on pro- and anti-inflammatory proteins as predicting biomarkers 
of post-stroke outcomes. 
Protein Associations to post-stroke outcomes Study 
CRP Higher levels have been associated to 
•   Larger infarct volume 
•   Severe stroke 
•   Post-stroke edema and infections 
•   Poor functional outcome 
•   Death 
•   Bustamante et al. 2016 
(reference 47)  
•   Yu et al. 2017 (reference 48) 
 
IL-6 Higher levels have been associated to 
•   Larger infarct volume 
•   Worse neurological symptoms 
•   Post-stroke infections  
•   Poor functional outcome 
•   Death 
•   Bustamante et al. 2016 
(reference 47)  
•   Doll et al. 2014 (reference 49) 
•   Whiteley et al. 2009 (reference 
50) 
TNF Higher levels have been associated to 
•   Larger infarct volume 
•   Worse neurological symptoms 
•   Poor outcome 3 months after stroke 
•   Bustamante et al. 2016 
(reference 47) 
•   Doll et al. 2014 (reference 49) 
IL-1b Higher levels have been associated to 
•   Severe stroke 
•   Poor functional outcome 
•   Bustamante et al. 2016 
(reference 47) 
•   Doll et al. 2014 (reference 49) 
IL-33 Higher levels have been associated to 
•   Smaller infarct volume 
•   Mild stroke measured as NIHSS 
•   Good functional outcome 
•   Qian et al. 2016 (reference 51) 
NIHSS, National Institutes of Health Stroke Scale; CRP, C-reactive protein; IL-6, interleukin 
6; TNF, tumor necrosis factor; IL-1b, interleukin 1b; IL-33, interleukin-33. 
 
Genetics 
Genetics can play a role in several aspects of stroke: genetic variations have been identified 
showing an association to risk of stroke in general, stroke subtypes and conditions associated 
with stroke such as hypertension and atrial fibrillation (52). Some studies have also suggested 
that post-stroke functional outcome might be influenced by genetics (53). 
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For instance, variations of the brain-derived neurotrophic factor (BDNF) gene have been 
associated with long-term neurological outcome, recurrent stroke and mortality as well as 
stroke recovery and response to rehabilitation treatment (53). Another example is genetic 
variations of Apo E that has been associated with stroke recovery (53). Other associations 
have been seen between genetic variations affecting serotonin signalling and post-stroke 
depression and variations in several different genes that affect the response to treatment with 
tissue plasminogen activator (tPA), warfarin and dabigatran (53). 
 
Novel biomarkers in the present study 
NFL 
Neurofilament light chain (NFL) is one of three subunits of neurofilament, a central nervous 
system (CNS) cell-type specific structural protein in the cytoskeleton of axons. Neurofilament 
is released into the extracellular space in response to axonal damage and later reaches both the 
cerebrospinal fluid (CSF) and the blood stream. The neurofilament subunits are suggested as 
biomarkers of neurodegenerative diseases since higher levels have been detected in patients 
with amyotrophic lateral sclerosis (ALS), Parkinson’s disease and Alzheimer’s disease among 
others. (54) 
 
Until recently, NFL has been measured in CSF only. Today, with the development of analyses 
with higher sensitivity for detection of the protein in blood it is possible to measure serum 
concentrations of NFL. For instance, one study found higher serum levels of NFL in patients 
with Alzheimer’s disease, Guillain-Barré-syndrome and ALS compared to patients with 
neurological diseases without brain damage and healthy controls. Serum concentrations were 
highly correlated to CSF levels (55). Elevated serum concentrations of NFL have also been 
 16 
observed in patients with multiple sclerosis (56) and mild traumatic brain injury (57) as well 
as TIA and ischemic stroke (58). 
 
GFRa1 
Glial cell-derived neurotrophic factor family ligands (GFLs) include 4 ligands (Table 4) 
which are members of the transforming growth factor-beta (TGF-b) superfamily. GFLs bind 
to glial cell-derived neurotrophic factor family receptor alpha (GFRa). Thereafter, the GFL-
GFRa-complexes bind to receptor tyrosine (RET) kinases which subsequently initiate an 
intracellular signalling cascade. (59) 
 
Table 4. Table of glial cell-derived neurotrophic factor family ligands (GFLs) and their 
receptors, glial cell-derived neurotrophic factor family receptor alpha (GFRa). 
Glial cell-derived neurotrophic factor 
family ligands (GFLs) 
Glial cell-derived neurotrophic factor 
family receptor alpha (GFRa) 
Glial cell-derived neurotrophic factor 
(GDNF) 
GFRa1 
Neurturin (NRTN) GFRa2 
Artemin (ARTN) GFRa3 
Persephin (PSPN) GFRa4 
	  
 
GDNF was first discovered in rat glioma, acting as a trophic factor for the embryonic 
development of midbrain dopamine neurons (59). Later on, GDNF has been found to play 
role in the development and functioning of other types of neuronal cells, in kidney 
development and differentiation of spermatogonia (59). In humans, mutations that interrupt 
the RET signalling pathway causes Hirschsprung’s disease which is characterized by absence 
of enteric ganglion in the intestines (59). GDNF has also been suggested as a treatment of 
Parkinson’s disease since several animal models has shown protective and facilitated recovery 
effects on dopamine neurons of this protein (59). Some experimental studies on animal 
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models of ischemic stroke have shown that the neuroprotective effect of GDNF is limited by 
the amount of GFRa1 available (60, 61), why it might be of greater interest to study the 
concentrations of the receptor than GDNF itself. 
 
MANF 
Mesencephalic astrocyte-derived neurotrophic factor (MANF) was originally discovered in 
vitro in a culture medium of type-1 astrocyte ventral mesencephalic cell line from rat as a 
neurotrophic factor protecting nigral dopaminergic neurons (62). It belongs to the novel 
neurotrophic family (NTF) (63) and was initially called arginine-rich mutated in early stage of 
tumours (ARMET) since mutations in the gene was found in early-stage tumours. However 
later on, the mutations were instead found to be common polymorphisms (64). 
 
The expression of MANF is upregulated by endoplasmic reticulum (ER) stress (63, 65). 
Pharmacological effects, viral infections, increased protein expression and other factors 
disturbing the protein folding process result in accumulation and aggregation of un- or 
misfolded proteins in the ER, causing ER stress and ER stress-induced apoptosis if the 
unfolded proteins are not taken care of (66). ER stress triggers can activate unfolded protein 
response (UPR) which is processes that promote protein folding (66). MANF has been shown 
to protect cells from ER stress, probably through mechanisms such as inhibition of ER stress-
induced apoptosis and involvement in the removal of un- or misfolded proteins (63, 65). In 
addition, MANF has shown neuroprotective effects in experimental studies of animal models 
of ischemic stroke (67, 68). 
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The importance of predictive biomarkers of post-stroke outcomes 
The heterogeneity of stroke etiology makes it difficult to predict outcomes and response to 
treatment. Finding biomarkers that separates stroke patients into subgroups with more 
resembling pathophysiological molecular mechanisms will not only facilitate the 
identification of patients in the risk zone of poor outcomes, but also make it easier to stratify 
study populations in clinical trials which in turn makes it possible to use smaller study 
populations while keeping the same statistical power. (69) 
 
The increasing incidence and decreasing mortality of stroke in young adults result in a greater 
number of young individuals living with various types of impairments and disabilities after 
stroke. Due to their longer life expectancy, these post-stroke consequences will affect their 
life for many years. At the same time, the social and economic consequences might be of 
greater extent since people in this period of life has other demands in their social as well as 
working lives. Therefore, it is of great interest to find biomarkers that contributes with 
additional predictive value and better identify individuals in the risk zone of poor post-stroke 
outcomes than the prognostic factors used today. 
 
AIM 
The aim of this study is to investigate if there is an association between circulating 
concentrations of three novel biomarkers and long-term outcomes after ischemic stroke. 
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MATERIAL AND METHODS 
Study population 
This study is based on the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS), 
which has been described in greater detail elsewhere (34, 70, 71). Patients with ischemic 
stroke aged 18-69 years were consecutively recruited within 10 days after stroke onset. The 
first 600 patients were recruited from Stroke Units at Skaraborgs sjukhus Skövde, Södra 
Älvsborgs sjukhus, Sahlgrenska Universitetssjukhuset (SU)/Östra and SU/Sahlgrenska 
between 1998 and 2003. 
 
The inclusion criteria were an episode of focal neurological deficits with acute onset and 
duration >24 hours or resulting in death indicating stroke and computed tomography (CT) 
scan or magnetic resonance imaging (MRI) of the brain excluding hemorrhage. Patients with 
etiologies other than ischemic stroke and/or diagnosis of advanced cancer, infectious hepatitis 
and HIV were excluded. 
 
For all participants, information about cardiovascular risk factors and sociodemographic 
factors were collected through structured questionnaires and physical examinations, including 
routine blood analyses. Stroke severity was determined using the Scandinavian stroke scale 
(SSS) (Appendix). Nowadays, NIHSS is more commonly used for this purpose and therefore, 
SSS was converted to NIHSS using an algorithm (72). Finally, stroke subtypes were classified 
according to the TOAST system (10). 
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Blood was drawn after an overnight fast between 8.30 and 10.30 a.m. Serum and plasma was 
isolated within 2 hours by centrifugation at 2000 x g at 4°C for 20 minutes. All samples were 
aliquoted and stored at -80 °C. 
 
Assessments of post-stroke outcomes 
Cause of death and recurrent events 
The Swedish Total Population Register (Folkbokföringen) was used for identification of non-
survivors. Cause of death was found in the Swedish Cause of Death Register and from the 
National Hospital Discharge Register (NHDR), which contains almost complete data (99%) 
on International Classification of Diseases, 10th Revision (ICD10) codes for hospital 
discharge diagnoses and procedures in Sweden. Recurrent vascular events were also identified 
in the NHDR. For recurrent stroke events, the NHDR was screened for ICD10 codes 160.0-
168.8. Diagnoses were confirmed by reviewing the corresponding medical record. 
 
Functional and neurological outcomes 
All cases were invited to a 3-month follow-up visit including SSS and mRS scoring as well as 
identification of recurrent strokes by a stroke neurologist. mRS scores of 0-2 were defined as 
good outcome and 3-6 as poor outcome. Cases recruited from the Stroke Unit at 
SU/Sahlgrenska were invited to an additional 7-year follow-up visit (n = 411) including a 
visit to the study nurse and a stroke neurologist. The study nurse performed mRS scoring and 
the neurologist performed NIHSS scoring to determine stroke-related neurological deficits. 
For cases included from Stroke Units other than SU/Sahlgrenska (n = 189), the study nurse 
performed mRS scoring through a telephone interview. 
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Substudy I 
In substudy I, serum concentrations of NFL were investigated in 595 cases. The analysis was 
performed using a single-molecule array (Simoa) method, a kind of digital ELISA where the 
protein is caught between two antibodies. With magnetic beads, which one of the antibodies is 
connected to, the protein-antibodies complex is brought into the well where detection of the 
protein occurs. This method makes it possible to detect proteins at subfemtomolar 
concentrations, i.e. at concentrations of less than 10-15 moles/litres. (73) 
 
Substudy II 
In substudy II, we went on to perform a pilot study of 92 proteins suggested as potential 
markers of neurobiological processes and/or neurological conditions by the so called 
Neurology panel (Olink) (74). For this study, we selected a subgroup of 220 cases in 
SAHLSIS. Plasma concentrations of the biomarkers were analysed using a multiplex 
immunoassay called proximity extension assay (PEA) (75) (Figure 1) where each protein in 
the assay is detected with two antibodies labelled with one DNA oligonucleotide each (A). 
The two antibodies bind to their target protein, bringing the oligonucleotides close enough to 
hybridize. Thereafter, the hybridized DNA sequence is used as a template for extension by a 
DNA polymerase resulting in a double-stranded DNA sequence unique for each protein (B). 
The DNA sequence is amplified by polymerase chain reaction (PCR) (C) and the amount is 
quantified using quantitive PCR (D). 
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Figure 1. Illustration of the PEA technology. (A) A pair of antibodies labelled with DNA 
oligonucleotides is used to detect the proteins in the assay. When the antibodies bind to the 
target protein (B) the oligonucleotides hybridize and the sequence is elongated by a DNA 
polymerase. The unique DNA sequence for each protein is (C) amplified by PCR and (D) 
quantified by quantitive PCR. PEA, proximity extension assay; PCR, polymerase chain 
reaction. (75) 
 
Values are presented as an arbitrary unit on Log2 scale, called normalized protein expression 
(NPX). NPX gives relative quantification and therefore, comparisons of values can only be 
performed for the same protein; values of two different proteins cannot be compared. High 
NPX values corresponds to high protein concentration. (76) 
 
Through literature research, two proteins considered to be of greatest interest for post-stroke 
outcomes, GFRa1 and MANF, were selected from the Olink Neurology panel for further 
investigation of their association with post-stroke outcomes. 
 
Statistical methods 
Statistics software SPSS statistics 24 for PC and 25 for MAC were used for all statistical 
analyses. Biomarker concentrations at 3 months were used in all analyses. The reason that we 
did not select the acute phase concentrations was for practical reasons, since the time point for 
this blood draw had a large interval, i.e. from day 0-10. Thus, the acute phase concentrations 
are dependent on the day of the blood draw and are also influenced by factors other than 
ischemic stroke itself such as pharmacological treatments and complications. NFL 
concentrations were not normally distributed and therefore, log transformed values were used 
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in all statistical analyses. 
 
Differences between the group with good outcome, mRS 0-2, and poor outcome, mRS 3-6, 
and between cases with high physical activity and sedentary lifestyle were examined using c2-
test for proportions, Mann-Whitney U-test for continuous, non-normally distributed variables 
and Student’s t-test for log transformed NFL values and GFRa1. 
 
Associations between biomarkers and NIHSS and mRS were examined using linear and 
logistic regression, respectively. Univariate and multivariate analyses were performed, 
adjusting for age and previous history of stroke before the index stroke (model 1) and for age, 
previous history of stroke before the index stroke and NIHSS at baseline (model 2). For 
GFRa1 and MANF, an additional model adjusting for age, previous history of stroke before 
the index stroke, NIHSS at baseline and physical activity <4 hours per week was performed 
as well (model 3). 
 
Age, previous history of stroke and NIHSS score at baseline were included as covariates in 
the multivariable analyses because they were significantly associated to outcomes and/or 
biomarker levels and could therefore influence the result. In addition, stroke severity (i.e. 
baseline NIHSS) in particular, but also age and previous history of stroke are well known 
predictors of post-stroke outcomes. Physical activity <4 h per week were included for GFRa1 
and MANF only. The reason for this was that preliminary results from our research group 
have shown an association between physical inactivity and long-term outcome measured as 
mRS. When concentrations of the three biomarkers were compared between cases with high 
physical activity and cases with a sedentary lifestyle, biomarker levels differed significantly 
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for GFRa1 (p = 0.012) and MANF (p = 0.017), but not for NFL (p = 0.27). Therefore, we 
chose to include this variable for GFRa1 and MANF only. 
 
The area under the receiver operating characteristic curve (AUC) was calculated for assessing 
the diagnostic accuracy of biomarker concentrations measured 3 months after the index stroke 
for good (mRS 0-2) versus poor (mRS 3-6) outcomes at 7 years. 
 
ETHICS 
The study was approved by the local Ethics Committee at the University of Gothenburg. 
Written informed consent was obtained from all participants prior to inclusion in the study. 
For patients who were unable to communicate, consent was obtained from their next of kin. 
 
RESULTS 
Substudy I 
Serum concentrations of NFL at 3 months were available in 546 patients, among whom 
NIHSS and mRS scores at 7 years were available for 272 and 438 patients, respectively. 
Forty-five patients had died before the 7-year follow-up. 
 
In the poor outcome group, cases were significantly older and had higher NIHSS scores at 
baseline and at 7 years (Table 5). Also, a larger proportion had diabetes mellitus and previous 
history of stroke before the index stroke. Serum concentrations of NFL was significantly 
higher in the poor outcome compared to the good outcome group (Table 5 and Figure 2). 
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Table 5. Baseline characteristics, serum concentrations of NFL and NIHSS at 7 years for the 
study participants in substudy I stratified in good and poor outcome according to mRS. 
 Good outcome at 7 years 
mRS 0-2 
(n = 293) 
Poor outcome at 7 years 
mRS 3-6 
(n = 181) 
Age, median (IQR) 57.5 (50.4-61.9) 62.3 (54.7-66.6)*** 
Male gender, n (%) 183 (63) 117 (65) 
Hypertension, n (%) 164 (56) 111 (61) 
Diabetes mellitus, n (%) 38 (13) 51 (28)*** 
Current smoker, n (%) 102 (35) 78 (43) 
Previous history of stroke, n (%) 44 (15) 48 (27)** 
NIHSS score at baseline, median 
(IQR) 
2.03 (0.7-4.1) 5.9 (2.5-13.6)*** 
NIHSS score at 7 years, median 
(IQR) 
0 (0-1) 6.5 (2.0-10.5)*** 
NFL (pg/ml) 3 months, n (%) 
median (IQR) 
278 (95) 
64.7 (34.8-135.6) 
160 (88) 
194.8 (69.8-411.4)*** 
Data are shown as median and interquartile range (IQR) or number (n) and percentage. 
Differences between the good (mRS 0-2) and poor (mRS 3-6) outcome groups were examined 
using c2-test for proportions, Mann-Whitney U-test for continuous, non-normally distributed 
variables and Student’s t-for serum concentrations of NFL on log transformed values. NIHSS, 
National Institutes of Health stroke scale; mRS, modified Rankin Scale; NFL, neurofilament 
light chain. *p <0.05, **p <0.01, ***p <0.001. 
 
 
Figure 2. Boxplot of log transformed NFL levels 3 months after the index stroke for good 
outcome (mRS 0-2) and poor outcome (mRS 3-6). mRS, modified Rankin Scale; NFL, 
neurofilament light chain. 
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Three-month NFL was significantly associated to 7-year NIHSS both in univariate and 
multivariate analyses (Table 6). The sensitivity analysis excluding cases with recurrent stroke 
before the 7-year follow-up performed on model 2 confirmed an association (βstd = 0.22, 95% 
CI 0.10-0.35, p = 0.001). 
 
Table 6. Linear regression analyses of associations for serum concentrations of NFL 3 
months after the index stroke and NIHSS score 7 years post-stroke. 
 βstd 95% CI for βstd p 
Log NFL 0.54 0.44-0.64 <0.001 
Log NFL1 0.53 0.43-0.63 <0.001 
Log NFL2 0.23 0.12-0.35 <0.001 
Standardized β and 95% confidence intervals for NIHSS score. The betas represent an 
estimate of how many standard deviations (SD) the NIHSS score will change per 1 SD 
increase in log transformed NFL concentrations. 1Model 1 including age and previous history 
of stroke before the index stroke. 2Model 2 including age, previous history of stroke before 
the index stroke and baseline NIHSS. NIHSS, National Institutes of Health Stroke Scale; 
NFL, neurofilament light chain. 
 
Three-month NFL was also significantly associated to mRS 7 years after the index stroke, 
both in the univariate and multivariate analyses (Table 7 and Figure 3). The sensitivity 
analysis excluding cases with recurrent stroke before the 7-year follow-up performed on 
model 2, confirmed an association (OR = 1.6, 95% CI 1.14-2.27, p = 0.007). 
 
Table 7. Logistic regression of associations for serum concentrations of NFL 3 months after 
the index stroke and outcome measured as mRS 7 years post-stroke. 
 OR CI p 
Log NFL 3 months 2.9 2.2-3.9 <0.001 
Log NFL 3 months1 2.9 2.2-3.9 <0.001 
Log NFL 3 monhts2 1.8 1.3-2.6 0.001 
Odds ratios and 95% confidence intervals for poor outcome (mRS 3-6) per 1 SD increase in 
log transformed NFL concentrations. 1Model 1 including age and previous history of stroke 
before the index stroke. 2Model 2 including age, previous history of stroke before the index 
stroke and baseline NIHSS. NIHSS, National Institutes of Health Stroke Scale; mRS, 
modified Rankin Scale; NFL, neurofilament light chain. 
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Figure 3. Forest plot of odds ratio and 95% confidence intervals for poor outcome (mRS 3-6) 
per 1 SD increase in log transformed NFL concentrations. Model 1 including age and 
previous history of stroke. Model 2 including age, previous history of stroke before the index 
stroke and baseline NIHSS. NIHSS, National Institutes of Health Stroke Scale; mRS, 
modified Rankin Scale; NFL, neurofilament light chain. 
 
The diagnostic accuracy of 3-month NFL for good (mRS 0-2) versus poor (mRS 3-6) 
outcome at 7 years were examined by assessing the AUC (Figure 4). 3-month NFL generated 
an AUC of 0.72 (95% CI 0.67-0.77). For baseline NIHSS in the study population for substudy 
I, the AUC was 0.74 (95% CI 0.69-0.79). 
0 1 2 3 4 5
OR
Univariat Model	  1 Model	  2
NFL
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Figure 4. ROC-curves for log transformed NFL concentrations and baseline NIHSS for good 
(mRS 0-2) versus poor (mRS 3-6) outcome at 7 years post stroke. ROC, Receiver operating 
characteristics; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin 
Scale; NFL, neurofilament light chain. 
 
Substudy II 
Plasma concentrations of GFRa1 and MANF at 3 months were available for 215 patients, 
among whom NIHSS and mRS scores at 7 years were available for 212 and 215 patients, 
respectively. 
 
In the poor outcome group, a larger proportion of cases had diabetes mellitus and previous 
history of stroke before the index stroke compared to the good outcome group (Table 8). In 
addition, they were less physically active. They also had higher NIHSS scores both at baseline 
and at 7 years. Plasma concentrations of GFRα1 (Table 8 and Figure 5) and MANF (Table 8 
and Figure 6) were significantly higher than in the good outcome group. 
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Table 8. Baseline characteristics, serum concentrations of GFRα1 and MANF and NIHSS at 
7 years for the study participants in substudy II stratified in good and poor outcome according 
to mRS. 
 Good outcome at 7 
years 
mRS 0-2 
(n = 183) 
Poor outcome at 7 years 
mRS 3-6 
(n = 37) 
Age, median (IQR) 55.2 (48.4-60.6) 57.8 (50.3-65.4) 
Male gender, n (%) 117 (64) 24 (65) 
Hypertension, n (%) 96 (53) 21 (57) 
Diabetes mellitus, n (%) 22 (12) 10 (27)* 
Current smoker, n (%) 62 (34) 16 (43) 
Previous history of stroke, n (%) 24 (13) 11 (30)* 
Moderate physical activity <4 hours per 
week = sedentary before stroke, n (%) 
18 (10) 14 (38)*** 
NIHSS score at baseline, median (IQR) 2.0 (0.7-4.2) 6.3 (3.1-15.4)*** 
NIHSS score 7 years, median (IQR) 0 (0-1) 5 (2-9)*** 
GFRα1 3 months, n (%) median (IQR) 180 (98) 
5.9 (5.6-6.1) 
35 (95) 
6.1 (5.9-6.4)*** 
MANF 3 months, n (%) median (IQR) 180 (98) 
6.0 (5.1-7.0) 
35 (95) 
6.9 (5.5-7.7)* 
Data are shown as median and interquartile range (IQR) or number (n) and percentage. 
Differences between the good (mRS 0-2) and poor (mRS 3-6) outcome groups were examined 
using c2-test for proportions, Mann-Whitney U-test for continuous, non-normally distributed 
variables and Student’s t-for GFRα1 values. NIHSS, National Institutes of Health stroke 
scale; mRS, modified Rankin Scale; GFRa1, glial cell-derived neurotrophic factor family 
receptor-alpha-1; MANF, mesencephalic astrocyte-derived neurotrophic factor. *p <0.05, **p 
<0.01, ***p <0.001. 
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Figure 5. Boxplot of GFRa1 levels 3 months after the index stroke for good outcome (mRS 
0-2) and poor outcome (mRS 3-6). mRS, modified Rankin Scale; GFRa1, glial cell-derived 
neurotrophic factor family receptor-alpha-1. 
 
 
Figure 6. Boxplot of MANF levels 3 months after the index stroke for good outcome (mRS 
0-2) and poor outcome (mRS 3-6). mRS, modified Rankin Scale; MANF, mesencephalic 
astrocyte-derived neurotrophic factor. 
 
Three-month levels of both GFRα1 and MANF were significantly associated to 7-year NIHSS 
in univariate and multivariate analyses when adjusting for age and previous history of stroke 
(Table 9). When also adjusting for baseline NIHSS, the significant association remained for 
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MANF but not for GFRα1 (Table 9). The association for MANF remained when additionally 
adjusting for physical activity (Table 9). 
 
The sensitivity analysis excluding cases with recurrent stroke before the 7-year follow-up was 
performed for model 2 and 3. For GFRα1, the association was still not significant for model 2 
(βstd = 0.07, 95% CI (-0.05)-0.19, p = 0.24) or 3 (βstd = 0.05, 95% CI (-0.07)-0.17, p = 0.42). 
For MANF, the association was borderline significant for model 2 (βstd = 0.11, 95% CI (-
0.002)-0.23, p = 0.05) and model 3 (βstd = 0.12, 95% CI (-1.11E-05)-0.24, p = 0.05). 
 
Table 9. Linear regression analyses of associations for serum concentrations of GFRa1 and 
MANF 3 months after the index stroke and outcome measured as NIHSS 7 years post-stroke. 
 bstd 95% CI for bstd p 
GFRa1 3 months 0.17 0.03-0.30 0.015 
MANF 3 months 0.14 0.0007-0.27 0.049 
GFRa1 3 months1 0.15 0.01-0.28 0.031 
MANF 3 months1 0.15 0.01-0.28 0.032 
GFRa1 3 months2 0.07 (-0.04)-0.19 0.206 
MANF 3 months2 0.12 0.008-0.23 0.036 
GFRa1 3 months3 0.07 (-0.05)-0.19 0.259 
MANF 3 months3 0.13 0.008-0.24 0.036 
Standardized β and 95% CI for NIHSS score. The betas represent an estimate of how many 
standard deviations (SD) the NIHSS score will change per 1 SD increase in arbitrary units for 
GFRa1 and MANF concentrations. 1Model 1 including age and previous history of stroke 
before the index stroke. 2Model 2 including age, previous history of stroke before the index 
stroke and baseline NIHSS. 3Model 3 including age, previous history of stroke before the 
index stroke, NIHSS acute and physical activity. NIHSS, National Institutes of Health Stroke 
Scale; mRS, modified Rankin Scale; GFRa1, glial cell-derived neurotrophic factor family 
receptor-alpha-1; MANF, mesencephalic astrocyte-derived neurotrophic factor. 
 
Three-month levels of both GFRα1 and MANF were significantly associated to 7-year mRS 
in univariate and multivariate models including age, previous history of stroke and baseline 
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NIHSS (Table 10 and Figure 7). However, the association was not retained for either GFRα1 
or MANF when additionally adjusting for physical activity (Table 10 and Figure 7). 
 
The sensitivity analysis excluding cases with recurrent stroke before the 7-year follow-up was 
performed on model 2 and 3. For GFRα1, the significant association remained (OR = 1.8, 
95% CI 1.10-3.09, p = 0.023) in model 2 but was still not significant in model 3 (OR = 1.5, 
95% CI 0.80-2.85, p = 0.21). For MANF, the association remained significant in model 2 (OR 
= 1.72, 95% CI 1.11-2.68, p = 0.016) and became significant in model 3 (OR = 1.75, 95% CI 
1.02-3.00, p = 0.041). 
 
Table 10. Logistic regression of the associations for serum concentrations of GFRa1 and 
MANF 3 months after the index stroke and outcome measured as mRS 7 years post-stroke. 
 OR 95% CI for OR p 
GFRa1 3 months 2.0 1.4-3.0 <0.001 
MANF 3 months 1.7 1.1-2.5 0.015 
GFRa1 3 months1 1.9 1.3-2.9 0.002 
MANF 3 months1 1.7 1.1-2.6 0.014 
GFRa1 3 months2 1.8 1.1-2.7 0.01 
MANF 3 months2 1.7 1.1-2.7 0.02 
GFRa1 3 months3 1.5 0.8-2.9 0.21 
MANF 3 months3 1.5 0.9-2.6 0.12 
Odds ratios and 95% confidence intervals for poor outcome (mRS 3-6) per 1 SD increase in 
arbitrary units for GFRa1 and MANF concentrations. 1Model 1 including age and previous 
history of stroke before the index stroke. 2Model 2 including age, previous history of stroke 
before the index stroke and baseline NIHSS. 3Model 3 including age, previous history of 
stroke before the index stroke, baseline NIHSS and physical activity. NIHSS, National 
Institutes of Health Stroke Scale; mRS, modified Rankin Scale; GFRa1, glial cell-derived 
neurotrophic factor family receptor-alpha-1; MANF, mesencephalic astrocyte-derived 
neurotrophic factor. 
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Figure 7. Forest plot of odds ratio and 95% confidence intervals for poor outcome (mRS 3-6) 
per 1 SD increase in arbitrary units for GFRa1 and MANF concentrations. Model 1 including 
age and previous history of stroke before the index stroke. Model 2 including age, previous 
history of stroke before the index stroke and baseline NIHSS. Model 3 including age, 
previous history of stroke before the index stroke and physical activity. NIHSS, National 
Institutes of Health Stroke Scale; mRS, modified Rankin Scale; GFRa1, glial cell-derived 
neurotrophic factor family receptor-alpha-1; MANF, mesencephalic astrocyte-derived 
neurotrophic factor. 
 
The diagnostic accuracy of 3-month GFRa1 and MANF for good (mRS 0-2) versus poor 
(mRS 3-6) outcome at 7 years were examined by assessing the AUC (Figure 8). GFRa1 
generated an AUC of 0.69 (95% CI 0.60-0.79) and MANF an AUC of 0.64 (95% CI 0.53-
0.74). For baseline NIHSS in the study population of substudy II, the AUC was 0.76 (95% CI 
0.67-0.85). 
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GFRα1
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Figure 8. ROC-curves for GFRa1 and MANF concentrations and baseline NIHSS for good 
(mRS 0-2) versus poor (mRS 3-6) outcome at 7 years post stroke. ROC, Receiver operating 
characteristics; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin 
Scale; GFRa1, glial cell-derived neurotrophic factor family receptor-alpha-1; MANF, 
mesencephalic astrocyte-derived neurotrophic factor. 
 
DISCUSSION 
In the present study, we have investigated the association between circulating concentrations 
of three novel biomarkers and long-term outcomes after ischemic stroke. Firstly, we 
investigated 595 ischemic stroke patients and found that serum concentrations of NFL at 3 
months after the index stroke were significantly higher in the group with poor outcome (mRS 
3-6) compared to the group with good outcome (mRS 0-2) at a 7-year follow-up. 
Furthermore, 3-month NFL was significantly and independently associated to both 7-year 
NIHSS and mRS. Next, we analysed plasma concentrations of GFRa1 and MANF in a 
subgroup of 220 patients. Three-month concentrations of these two biomarkers were also 
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significantly higher in cases with poor compared to those with good outcome at 7 years and 
both biomarkers were significantly associated to 7-year NIHSS and mRS. 
 
The finding that higher serum levels of NFL were associated to poor outcome was expected 
since it is a known marker of brain damage. However, the few previous studies that has been 
conducted on associations between NFL concentrations and stroke outcomes have been 
unsuccessful in showing an independent association. One study on 487 patients with ischemic 
stroke found an association between serum NFL and 3-month mRS in the univariate analysis 
that did not remain when adjusting for covariates (58). Reasons for this might be the use of 
the electrochemiluminescence immunoassay for measurement of NFL concentrations which is 
a less sensitive method compared to the Simoa method used in the present study (73) and that 
NFL concentrations were measured within 24 hours of stroke onset, which is too early to 
catch the peak in circulating concentrations of NFL after ischemic stroke according to 
previous studies (77, 78). Another study on 31 patients with ischemic stroke due to non-
traumatic cervical artery dissection also found an association between serum NFL and poor 
outcome at 3 months that did not remain in multivariate analyses (78). Again, the less 
sensitive electrochemiluminescence immunoassay was used and also the sample size was 
small, which may influence the results. 
 
As far as we are aware, this is the first study to investigate the association between plasma 
concentrations of GFRa1 and MANF and stroke outcomes. Previous experimental studies 
show that GDNF, the ligand of GFRa1, reduces the size of cerebral infarctions in rats. This is 
presumably mediated by inhibition of nitric oxide (NO) synthesis, which is believed to be 
involved in the neurotoxicity during brain ischemia (79). It has also been shown that the 
neuroprotective effect of GDNF is depending on the amount of GFRa1 available. In one 
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study, GFRa1 (+)/(+) and GFRa1 (+)/(-) mice with induced occlusion of arteria cerebri 
media were treated with GDNF administered into the cerebral cortex. GFRa1 (+)/(+) mice 
had better preserved motor function and smaller infarctions compared to the GFRa1 (+)/(-) 
and untreated mice, indicating that the amount of GFRa1 is a limiting factor of the effect of 
GDNF (60). In line with these results, another study has shown an increase in GFRa1 mRNA 
levels in response to both ischemia and reperfusion in rats and just a slight increase in GDNF 
mRNA levels, which suggests that levels of GFRa1 is a regulating factor of the GDNF 
neuroprotective effect (61). 
 
With regards to MANF, cerebral ischemia causes endoplasmic reticulum (ER) stress which 
contributes to neuronal death. As previously mentioned, the expression of MANF is 
upregulated by ER stress and it has been shown that the expression of MANF is upregulated 
in both neurons and glial cells in response to ischemia in ischemic stroke rat models (65). 
From other experimental studies on ischemic stroke, it has been shown that treatment with 
MANF, both as injections into the ventricular system of the brain (67) and as adeno-
associated virus serotype 7 encoding human MANF (68), reduces infarct volume and 
improves neurological recovery. 
 
Thus, both GFRa1 and MANF have been shown to have neuroprotective effects in animal 
models of ischemic stroke. Consequently, elevated levels of these biomarkers would be 
anticipated to associate with good outcome, but we found associations in the opposite 
direction. The reasons for this remain elusive. To our knowledge, there are no previous 
clinical studies on circulating levels of GFRa1 and MANF. Thus, further studies are clearly 
warranted to be able to interpret our results. 
 
 37 
Strengths of the present study include a large study sample of consecutive and well 
characterized cases that have been followed for a long period of time and outcomes have been 
assessed by both NIHSS and mRS. Blood sampling was strictly standardized and for 
measurement of NFL, we used the most sensitive method available. However, there are also 
several limitations. It can not be excluded that the results are influenced by confounders not 
included in our multivariable analyses. In addition, all cases were <70 years of age and of 
mainly European ancestry and therefore, our results might not be representative for stroke 
patients of older ages or for stroke patients of other ethnicities. Furthermore, the loss to 
follow-up might have influenced our results. 
 
CONCLUSIONS 
In this master thesis, associations between three novel biomarkers and outcomes after 
ischemic stroke were investigated. We identified independent associations to outcomes for all 
three biomarkers studied. As NFL is a known marker of brain damage, it was expected that 
cases with poor outcomes would have higher concentrations. We observed highest levels of 
NFL at 3 months after index stroke, but additional studies are needed in order to evaluate the 
most informative time point for NFL as a predictor of stroke outcomes. From what is known 
from previous experimental studies, GFRa1 and MANF both have neuroprotective effects in 
ischemic stroke and therefore it was unexpected that concentrations of these biomarkers were 
higher in cases with poor outcome. Thus, further studies are clearly needed in order to 
increase the knowledge about the role of these two biomarkers for stroke outcomes and to 
understand why high levels are associated with poor outcomes. The ultimate goal for future 
studies would be to find a combination of circulating biomarkers that predicts outcomes after 
ischemic stroke with high sensitivity and specificity. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Stroke innebär att hjärnan får brist på syre, antingen p.g.a. en blödning som trycker på hjärnan 
eller p.g.a. en blodpropp som täpper till ett blodkärl som går till hjärnan. När en del av 
hjärnan inte får tillräckligt mycket syre kommer dess nervceller att dö. Beroende på i vilken 
del av hjärnan som syrebristen uppstår kan olika symtom uppkomma såsom förlamning av 
ansikte, arm och/eller ben, försämrad känsel eller talsvårigheter. När en blodpropp orsakar 
syrebristen kallas det för hjärninfarkt, vilket utgör cirka 85% av all stroke i Sverige och är den 
form som är studerad i det här arbetet. 
 
Patienter som överlever en hjärninfarkt återhämtar sig mycket olika. Vissa blir helt återställda 
medan andra har många kvarstående funktionsnedsättningar som kan resultera i att de inte kan 
återgå till sitt arbete och att de behöver mycket hjälp och stöd i sin vardag. De som återhämtar 
sig dåligt kan till exempel ha kvarstående förlamning, försämrad känsel eller talsvårigheter, 
men också andra symtom såsom kraftig trötthet, minnes- och koncentrationssvårigheter eller 
depression. 
 
Idag vet man att patienter som får syrebrist i en stor del av hjärnan, som får många och svåra 
symtom av sin hjärninfarkt och som får upprepade hjärninfarkter oftast återhämtar sig sämre. 
Det finns dock en stor variation i återhämtning som inte bara kan förklaras av de prediktiva 
faktorer som vi känner till idag och det finns därför ett behov av att hitta så kallade 
biomarkörer, t. ex. proteiner som kan mätas genom ett blodprov, som kan hjälpa till att 
identifiera patienter som befinner sig i riskzonen för dålig återhämtning. I det här arbetet har 
vi tittat på tre proteiner som kan mätas genom ett blodprov för att se om de kan förutsäga 
vilka patienter som kommer att återhämta sig dåligt efter sin hjärninfarkt. 
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Vi har kunnat påvisa att högre nivåer av de studerade proteinerna i blodet hos patienter som 
genomgått en hjärninfarkt har en koppling till sämre återhämtning. Dessa resultat behöver 
dock verifieras i andra studier för att med större säkerhet kunna säga att resultatet i det här 
arbetet stämmer. Framtida studier behöver dels mäta de tre proteinerna som vi har undersökt i 
den här studien och dels undersöka fler proteiner för att kunna hitta den bästa kombinationen 
av proteiner som kan förutsäga vilka patienter som riskerar dålig återhämtning efter en 
hjärninfarkt. 
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APPENDIX
 
 
 
SCANDINAVIAN Patient Name: ____________________________ 
STROKE Rater Name: ____________________________ 
SCALE Date: ____________________________ 
 
 
 
 
Function Score Prognostic Long Term 
  Score Score 
 
Consciousness: 
-fully conscious 6 ____ 
-somnolent, can be awaked to full consciousness 4 
-reacts to verbal command, but is not fully conscious  2 
 
Eye movement:  
-no gaze palsy  4 ____ 
-gaze palsy present  2 
-conjugate eye deviation  0 
 
Arm, motor power *: 
-raises arm with normal strength  6 ____ ____ 
-raises arm with reduced strength  5 
-raises arm with flexion in elbow  4 
-can move, but not against gravity 2 
-paralysis 0 
 
Hand, motor power *:  
-normal strength  6  ____ 
-reduced strength in full range  4 
-some movement, fingertips do not reach palm  2 
-paralysis  0 
 
Leg, motor power *: 
-normal strength  6 ____ ____ 
-raises straight leg with reduced strength  5 
-raises leg with flexion of knee  4 
-can move, but not against gravity  2 
-paralysis  0 
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Orientation: 
-correct for time, place and person  6  ____ 
-two of these  4 
-one of these  2 
-completely disorientated  0 
 
Speech:  
-no aphasia  10  ____ 
-limited vocabulary or incoherent speech 6 
-more than yes/no, but not longer sentences  3 
-only yes/no or less  0 
 
Facial palsy:  
-none/dubious  2  ____ 
-present  0 
 
Gait:  
-walks 5 m without aids  12  ____ 
-walks with aids  9 
-walks with help of another person 6 
-sits without support  3 
-bedridden/wheelchair  0 
 
Maximal Score ____ 22 48 
 
 
* Motor power is assessed only on the affected side. 
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